Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03 | OncLive
Trastuzumab deruxtecan versus trastuzumab emtansine in patient…
Dec 22, 2022
onclive.com
LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2 ) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05 | OncLive
LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (…
6 months ago
onclive.com
FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer: Trastuzumab Deruxtecan (T-DXd)
FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer…
Aug 5, 2022
mskcc.org
Targeted Therapy - National Breast Cancer Foundation
1:52
Targeted Therapy - National Breast Cancer Foundation
2K views4 months ago
nationalbreastcancer.org
HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer | OncLive
9:13
HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tuca…
Feb 5, 2024
onclive.com
Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1) | OncLive
Expert Perspectives on Clinical Experience with Ado-Trastuzuma…
Feb 7, 2023
onclive.com
HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer | OncLive
11:33
HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phas…
Jan 25, 2024
onclive.com
ESMO Breast 2025 Insights: Tucatinib & Trastuzumab for Previ…
85 viewsMay 22, 2025
vumedi.com
Breast cancer drug ‘found to reduce risk of disease progression’
Sep 18, 2021
aol.co.uk
Dr O’Brien on Tucatinib Plus Trastuzumab/Capecitabine for Lep…
Aug 22, 2024
onclive.com
ESMO 2025 Summary: Breast Cancer Highlights From monarch…
82 views6 months ago
vumedi.com
Overview of Current ADCs in Breast Cancer | OncLive
Aug 21, 2024
onclive.com
ASCO 2022: Practice-Changing Findings Identify HER2-Low as a T…
Jun 5, 2022
mskcc.org
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in …
Jun 24, 2022
ascopost.com
Dr McAndrew on the HER2CLIMB-02 Trial in HER2 Breast Cancer | Onc…
Feb 15, 2024
onclive.com
3:27
Update from KATHERINE on Adjuvant T-DM1 for Residual Inva…
Jan 11, 2024
targetedonc.com
Dr Krill-Jackson on the Practice-Changing Effect of T-DXd in HER2 …
Oct 12, 2023
onclive.com
T-DXd Versus T-DM1 in HER2 MBC: Results of DESTINY-Breast03 | On…
Oct 28, 2021
onclive.com
14:08
HER2 Amplification and Breast Cancer Part 1
24.8K viewsNov 10, 2014
YouTubeElliot Nicholson
3:20
How Monoclonal Antibodies Treat Cancer
177.5K viewsJun 30, 2020
YouTubeNational Cancer Institute
8:42
Trastuzumab Deruxtecan in HER2+ Breast Cancer
509 viewsJul 7, 2020
YouTubeTargeted Oncology
5:05
Anti-HER2 Mechanisms of Approved HER2 Inhibitors
166.8K viewsApr 30, 2013
YouTubeHMP Global
0:34
Herceptin: Mechanism of action
52.7K viewsAug 2, 2007
YouTubeCancerQuest-CJ
1:31
Current Treatment Options for Patients With HER2-Positive Meta…
3.4K viewsApr 1, 2019
YouTubeTargeted Oncology
1:11
Neratinib/T-DM1 Doses Recommended for Phase II Trial i…
214 viewsDec 12, 2018
YouTubeTargeted Oncology
4:34
Paclitaxel With Pertuzumab Plus Trastuzumab in Metastatic Breast …
2.3K viewsAug 28, 2013
YouTubeOncLive
6:48
Pertuzumab adds 16 months survival to trastuzumab plus chem…
967 viewsNov 11, 2014
YouTubeecancer
3:50
Herceptin (trastuzumab) for HER2-Positive Breast and Stomach Cancer
45.2K viewsOct 21, 2015
YouTubeOncology Associates
3:19
Study of Targeted Therapy for HER2-Positive Metastatic Breast …
4.5K viewsAug 23, 2019
YouTubeDana-Farber Cancer Institute
4:27
Study of Immunotherapy Combinations for Patients with HE…
1.8K viewsApr 4, 2019
YouTubeDana-Farber Cancer Institute
See more videos
Static thumbnail place holder